Phaseline

Companies › Lepu Biopharma

Lepu Biopharma: clinical trials, targets and expected readouts

4 active drug programs in 37 registered trials: 24 Phase 2, 8 Phase 1, 5 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MRG003
TIGIT inhibitor
–Phase 3Squamous Cell Carcinoma of the Head and Neck; Recurrent or Metastatic Nasopharyngeal Carcinoma; Advanced Solid TumorsDec 2026
Pucotenlimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Recurrent or Metastatic Nasopharyngeal Carcinoma; Head and Neck Squamous Cell Carcinoma; Advanced Solid Tumors; Hepatocellular Carcinoma …Aug 2027
Becotatug Vedotin for Injection
Anti-TROP-2 antibody-drug conjugate
TACSTD2Phase 2Head and Neck Squamous Cell CarcinomaDec 2027
MRG006A
uncertain mechanism
–Phase 1Advanced Solid Tumors; Hepatocellular CarcinomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07312422PucotenlimabPhase 1Pancreatic CancerOncologyApr 2026
NCT06524466PucotenlimabPhase 2Resectable Hepatocellular CarcinomaOncologyDec 2026
NCT06456892PucotenlimabPhase 1RhabdomyosarcomaOncologyDec 2026
NCT05126719MRG003Phase 2Recurrent or Metastatic Nasopharyngeal CarcinomaOncologyDec 2026
NCT07386158PucotenlimabPhase 2VorolanibOncologyDec 2026
NCT07814287PucotenlimabPhase 2Head and Neck Squamous Cell Carcinoma, HNSCCOncologyDec 2026
NCT07105852PucotenlimabPhase 2CholangiocarcinomaOncologyJul 2027
NCT05688605MRG003Phase 1Advanced Solid TumorsOncologyAug 2027
NCT05688605PucotenlimabPhase 1Advanced Solid TumorsOncologyAug 2027
NCT07448142PucotenlimabPhase 2Colorectal Cancer (CRC)OncologySep 2027
NCT07665190PucotenlimabPhase 2Hypopharyngeal Squamous Cell CarcinomaOncologyOct 2027
NCT07665190PucotenlimabPhase 2Hypopharyngeal Squamous Cell CarcinomaOncologyOct 2027
NCT05751512MRG003Phase 3Squamous Cell Carcinoma of the Head and NeckOncologyDec 2027
NCT07586124PucotenlimabPhase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2027
NCT07586124Becotatug Vedotin for InjectionPhase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2027
NCT07093970MRG006APhase 1Advanced Solid TumorsOncologyDec 2027
NCT06969534PucotenlimabPhase 2Lymphoepithelioma-like CarcinomaOncologyDec 2027
NCT06889610PucotenlimabPhase 2Triple Negative Breast Cancer MetastaticOncologyDec 2027
NCT06770270PucotenlimabPhase 2Rectal CancerOncologyDec 2027
NCT07479485PucotenlimabPhase 1Hepatocellular CarcinomaOncologyApr 2028
NCT07479485MRG006APhase 1Hepatocellular CarcinomaOncologyApr 2028
NCT07518979PucotenlimabPhase 2Penile CancerOncologyMay 2028
NCT07464366PucotenlimabPhase 2Salivary Gland CarcinomasOncologyMay 2028
NCT07632339PucotenlimabPhase 2Head and Neck CancerOncologyJun 2028
NCT06192797PucotenlimabPhase 2Cholangiocarcinoma Non-resectableOncologyJun 2028
NCT07712029PucotenlimabPhase 2Advanced Refractory Solid TumorsOncologyAug 2028
NCT07896668PucotenlimabPhase 2Breast CancerOncologySep 2028
NCT07884188PucotenlimabPhase 2Metastatic Colorectal CancerOncologyOct 2028
NCT07235566PucotenlimabPhase 2Thyroid CancerOncologyApr 2029
NCT07497919PucotenlimabPhase 2Penile CancerOncologyMay 2029
NCT06976190MRG003Phase 3Recurrent or Metastatic Nasopharyngeal CarcinomaOncologyMay 2029
NCT06976190PucotenlimabPhase 3Recurrent or Metastatic Nasopharyngeal CarcinomaOncologyMay 2029
NCT06959108PucotenlimabPhase 2Locally Advanced Head and Neck Squamous Cell CarcinomaOncologyJun 2029
NCT07750067PucotenlimabPhase 2Melanoma MetastaticOncologyJul 2030
NCT07054307PucotenlimabPhase 1Penile CancerOncologyJul 2030
NCT07524452PucotenlimabPhase 3Locally Advanced Head and Neck Squamous Cell CarcinomaOncologyFeb 2031
NCT07528209PucotenlimabPhase 3Rectal CancerOncologyApr 2032

Targets

PDCD1 (1) TACSTD2 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical AstraZeneca Innovent Biologics (Suzhou) Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Merck & Co. (MSD) Ono Pharmaceutical Mabwell (Shanghai) Bioscience

Companies built like this

Innovent Biopharmaceutical Technology (Hangzhou) BeiGene mAbxience Research Genfleet Therapeutics (Shanghai) Klus Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.